XML 50 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Agreements - Gilead (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Dec. 19, 2018
USD ($)
item
$ / shares
shares
Jun. 30, 2019
USD ($)
$ / shares
shares
Jun. 30, 2019
USD ($)
$ / shares
Jun. 30, 2018
USD ($)
$ / shares
shares
Jun. 30, 2019
USD ($)
$ / shares
Agreements          
Sale of common shares (in shares) | shares   3,000,000   6,164,000  
Purchase price (in dollars per share) | $ / shares   $ 15.00 $ 15.00 $ 14.00 $ 15.00
Sale of common shares     $ 42,022 $ 77,835  
Revenue received     5,039   $ 8,145
Gilead          
Agreements          
Number of programs | item 3        
Option exercise period 90 days        
Upfront payment received $ 50,000        
Potential milestone payments 475,000        
Total potential milestone payments 1,425,000        
Refundable payments under the agreement $ 0        
Sale of common shares (in shares) | shares 980,392        
Purchase price (in dollars per share) | $ / shares $ 30.60        
Sale of common shares $ 30,000        
Maximum number of program antibodies to be notified which satisfies development criteria | item 2        
Transaction price $ 80,000        
Research collaboration term         3 years
Equity investment included in transaction price 17,100        
Contract liability 62,900        
Securities premium   $ 12,900 12,900   $ 12,900
Revenue received     $ 5,000   $ 8,100
Gilead | Development milestones          
Agreements          
Potential milestone payments $ 25,000